Regeneron extends Ebola treatment deal with US health agency in $270m agreement

Regeneron Pharmaceuticals has extended its agreement with the US Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of its Ebola treatment Inmazeb for US preparedness, in a deal worth about $270 million.

Under the extended agreement, announced on Monday, Regeneron expects to deliver additional doses of Inmazeb to the US government through 2031. The deal expands a procurement agreement first signed in 2020, the company said.

Inmazeb is a three-antibody cocktail of atoltivimab, maftivimab and odesivimab-ebgn. It was the first Ebola treatment approved by the US Food and Drug Administration, in 2020, for infection caused by Zaire ebolavirus, and has been administered to hundreds of patients since 2019. In a clinical trial it reduced mortality by about 55 percent compared with an active control treatment in patients with low viral load.

The agreement comes as a separate Ebola strain, Bundibugyo, drives the current outbreak in Africa. Reuters reports there is no approved specific antiviral treatment or licensed vaccine for Bundibugyo, and that Regeneron is testing its experimental therapy maftivimab as a potential treatment for that strain.

The outbreak, first reported in the Democratic Republic of Congo in May, has now spread to four countries across East, Central and West Africa — the widest geographic spread of any Ebola outbreak on the continent, according to Reuters. It has infected nearly 10,000 people and killed more than 4,800 in Congo.

Sources

• Reuters: “Regeneron extends US agreement for additional supply of Ebola treatment” — https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-extends-us-agreement-additional-supply-ebola-treatment-2026-10-26/
• Regeneron Pharmaceuticals via GlobeNewswire: “Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness” — https://usanewshour.com/regeneron-extends-agreement-with-barda-to-provide-additional-supply-of-ebola-treatment-inmazeb-for-u-s-preparedness/404063/